| Autor: |
Rebecca V; Johns Hopkins University., Jagirdar K, Portuallo M, Wei M, Wilhide M, Bravo J, Robertson B, Alicea G, Aguh C, Xiao M, Godok T, Fingerman D, Brown G, Herlyn M; The Wistar Institute., Guo B, Toska E; Johns Hopkins., Zabransky D; Johns Hopkins University., Wubbenhorst B, Nathanson K; University of Pennsylvania., Kwatra S, Goyal Y, Ji H, Liu Q; The Wistar Institute. |
| Jazyk: |
angličtina |
| Zdroj: |
Research square [Res Sq] 2023 Apr 20. Date of Electronic Publication: 2023 Apr 20. |
| DOI: |
10.21203/rs.3.rs-2817876/v1 |
| Abstrakt: |
Patients with metastatic acral lentiginous melanoma (ALM) suffer worse outcomes relative to patients with other forms of cutaneous melanoma (CM), and do not benefit as well to approved melanoma therapies. Identification of cyclin-dependent kinase 4 and 6 (CDK4/6) pathway gene alterations in > 60% of ALMs has led to clinical trials of the CDK4/6 inhibitor (CDK4i/6i) palbociclib for ALM; however, median progression free survival with CDK4i/6i treatment was only 2.2 months, suggesting existence of resistance mechanisms. Therapy resistance in ALM remains poorly understood; here we report hyperactivation of MAPK signaling and elevated cyclin D1 expression are a unified mechanism of both intrinsic and acquired CDK4i/6i resistance. MEK and/or ERK inhibition increases CDK4i/6i efficacy in a patient-derived xenograft (PDX) model of ALM and promotes a defective DNA repair, cell cycle arrested and apoptotic program. Notably, gene alterations poorly correlate with protein expression of cell cycle proteins in ALM or efficacy of CDK4i/6i, urging additional strategies when stratifying patients for CDK4i/6i trial inclusion. Concurrent targeting of the MAPK pathway and CDK4/6 represents a new approach to improve outcomes for patients with advanced ALM. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
